Percutaneous Coronary Intervention During the Shortage of Iodinated Contrast
Journal of Invasive Cardiology · 2024
DOI: 10.25270/jic/24.00242 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Invasive Cardiology, 2024. Verfasst von Zachary Gertz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia. Email: zachary.gertz@vcuhealth.org. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Contrast Media, Acute Kidney Injury, Coronary Artery Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: A recent coronavirus-related factory shutdown led to a global shortage of iodinated contrast. The authors evaluated how the contrast shortage impacted percutaneous coronary interventions (PCI). METHODS: Using a statewide database incorporating CathPCI registry data from 19 hospitals, the authors evaluated 2 time periods: pre-shortage (May 1, 2021 - April 30, 2022) and during the shortage (May 1, 2022 - October 31, 2022). They compared procedure volumes, patient and procedure characteristics, and short-term outcomes, including acute kidney injury (AKI). Of primary interest was the difference in contrast volume per PCI and the incidence of AKI between periods. RESULTS: There were 8980 patients treated pre-shortage and 4046 during the shortage. Procedure volumes per hospital remained similar, as did patient characteristics. Multivessel procedures declined during the shortage (45.3% vs 42.8%, P = .007). There was a significant decline in contrast per procedure (149.9 ± 68.1 mL to 137.5 ± 62.4 mL per case, P less than .0001) that began at the start of the shortage and continued throughout. There were no differences in patient outcomes, including AKI (7.9% vs 7.4%, P = .40), between study periods. When limited to patients at increased risk of AKI, there remained no difference in AKI between the study periods, despite a similar decrease in contrast volume in that cohort. Multivariable analysis showed a strong correlation between baseline risk of AKI and subsequent AKI (P less than .0001), but no impact of procedure characteristics or time period. CONCLUSIONS: The global shortage of iodinated contrast led to a significant decline in contrast use during PCI, with no impact on patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia. Email: zachary.gertz@vcuhealth.org.
- Division of Cardiology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia.
- Division of Cardiac Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia.
- Heart and Vascular Institute, Inova Fairfax Hospital, Fairfax, Virginia.
- Division of Cardiothoracic Surgery, Department of Surgery, Virginia Commonwealth University, Richmond, Virginia.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Gertz, Z., Mitchell, B. K., Kontos, M. C., Teman, N. R., Norman, A., Ahmad, R., Strobel, R. J., Damluji, A. A., Shor, R. A., Spier, A., & Qauder, M. A. (2024). Percutaneous Coronary Intervention During the Shortage of Iodinated Contrast. Journal of Invasive Cardiology. https://doi.org/10.25270/jic/24.00242
Vancouver
Gertz Z, Mitchell BK, Kontos MC, Teman NR, Norman A, Ahmad R, et al. Percutaneous Coronary Intervention During the Shortage of Iodinated Contrast. Journal of Invasive Cardiology. 2024. doi:10.25270/jic/24.00242
BibTeX
@article{Gertz2024,
author = {Gertz, Zachary and Mitchell, Brian K and Kontos, Michael C and Teman, Nicholas R and Norman, Anthony and Ahmad, Raza and Strobel, Raymond J and Damluji, Abdulla A and Shor, Robert A and Spier, Alan and Qauder, Mohammed A},
title = {Percutaneous Coronary Intervention During the Shortage of Iodinated Contrast},
journal = {Journal of Invasive Cardiology},
year = {2024},
doi = {10.25270/jic/24.00242}
}
EUVIMED